• Product NameFurosemide,Frusemide
  • CasNo. 54-31-9
  • MFC12H11ClN2O5S
  • MW330.749
  • Purity
  • Appearancewhite to light yellow crystal powder
  • Packing
  • Contact usInquiry

Product Details

CasNo: 54-31-9

MF: C12H11ClN2O5S

Appearance: white to light yellow crystal powder

Excellent chemical plant bulk supply Furosemide,Frusemide 54-31-9

  • Molecular Formula:C12H11ClN2O5S
  • Molecular Weight:330.749
  • Appearance/Colour:white to light yellow crystal powder 
  • Melting Point:220 °C 
  • Refractive Index:1.6580 (estimate) 
  • Boiling Point:582.1 °C at 760 mmHg 
  • PKA:pKa 3.8 (Uncertain) 
  • Flash Point:305.9 °C 
  • PSA:131.01000 
  • Density:1.606 g/cm3 
  • LogP:3.74480 

Furosemide(Cas 54-31-9) Usage

Efficient diuretics

Furosemide, is a class of efficient sulfonamide diuretics acting on the medullary loop of the ascending branch of the medulla,it has a strong and short-term diuretic effect,which can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphate and so on. It Mainly inhibits Na + and Cl-reabsorption in medullary and cortex of the medullary loop ascending branch crude segment , it can promote the excretion of sodium, chloride and potassium and affect the formation of renal medullary high osmotic pressure,it can interfer the process of concentration and dilution of urine, and it can increase urine output. This product can inhibit the activity of prostaglandin decomposition enzyme ,make the content of prostaglandin E2 increase,it has effect on expansion of blood vessels, it also plays a role in the proximal tubule, glomerular filtration,it can increase renal blood flow,and adjust renal blood flow distribution,and reduce blood flow so that the cortex surface blood flow increases,it promotes diuresis, its effect is fast and strong, it is used for other diuretics invalid cases. Clinically it is used for the treatment of cardiac edema, renal edema, cirrhosis ascitic fluid, peripheral edema caused by dysfunction or vascular disorders , and it may contribute to an upper urinary tract stones excretion. Administration intravenously can treat brain edema, it also can accelerate the excretion of toxic substances in cerebral edema in poisoning . Note that when the diuretic furosemide is used, since the excretion of urine Cl-, Na +, K +, H + is increasing, while the excretion of HCO3-is not increasing, long-term repeated drug use or large quantities of drugs can cause low salt syndrome, low chlorine and low potassium alkalosis. In recent years, researchers find that inhalation of furosemide can have a significant effect on asthma, it is like cromolyn sodium, which through inhibition of allergic mediator release, it can inhibit the release of the neurotransmitter acetylcholine and substance P, which may be related to inhibiting chloride ions into the cell membranes of respiratory tract. Clinically,it is used in exercise-induced asthma, immediate and delayed type antigen-induced asthma. The above information is edited by the lookchem of Tian Ye.

production method

2,4-dichlorobenzoic acid (see 12740) by sulfochlorination,ammoniation, acidification ,dichloro-5-sulfamoyl-benzoic acid is obtained. Then after condensation with the chaff amine , furosemide is produced.

Toxicity grading

Middle toxic

Acute toxicity

Oral-rat LD50: 2600 mg/kg; Oral-Mouse LD50: 2200 mg/kg.

Flammability and hazard characteristics

Combustible; fire decomposition produces toxic nitrogen oxides; sulfur oxides and chlorides smoke.

Storage Characteristics

Ventilated, low-temperature ,dry storeroom.

Extinguishing agent

Water, carbon dioxide, dry powder,sandy soil.

Manufacturing Process

10.8 grams of 3-sulfamyl-4,6-dichlorobenzoic acid (0.04 mol) and 11.7 grams of furfurylamine (0.12 mol) are heated in 30 cc of diethyleneglycoldimethylether for 6 hours under reflux. When pouring the reaction mixture into 300 cc of 1 N hydrochloric acid, the reaction product is immediately separated off in the form of crystals. The light-yellow crude product is purified by dissolving it in 100 cc of warm 1 N sodium bicarbonate solution, precipitation by means of hydrochloric acid and subsequent recrystallization from ethanol/water, with addition of charcoal. Colorless prisms are obtained which decompose at 206°C while adopting a brown coloration, and with evolution of gas.

Therapeutic Function

Diuretic

Air & Water Reactions

Light sensitive. Air sensitive. Slightly soluble in water.

Reactivity Profile

Furosemide may undergo hydrolysis at sufficiently low pH. The pH of aqueous solutions should be maintained in the basic range to prevent hydrolysis. Alcohol has been shown to improve the stability of Furosemide. Incompatible with strong oxidizing agents .

Hazard

Poison; moderately toxic; teratogen; questionable carcinogen; mutagen.

Fire Hazard

Flash point data for Furosemide are not available; however, Furosemide is probably combustible.

Biological Activity

Loop diuretic that inhibits the Na + /2Cl - /K + (NKCC) cotransporter. Also acts as a non-competitive antagonist at GABA A receptors with ~ 100-fold greater selectivity for α 6-containing receptors than α 1-containing receptors.

Biochem/physiol Actions

Inhibits ion co-transport in the kidney.

Mechanism of action

Furosemide is a highly effective and quick-acting diuretic whose action, like all of the examined loop diuretics, is associated with blocking reabsorption of ions in the ascending bend of Henle’s loop. It is used for edema syndrome of various origins, edema of the lungs and brain, chronic renal insufficiency, some forms of hypertonic crises, and poisoning by barbiturates and other compounds excreted mainly with urine.

Side effects

Clinical toxicity of furosemide and other loop diuretics primarily involves abnormalities of fluid and electrolyte balance. As with the thiazide diuretics, hypokalemia is an important adverse effect that can be prevented or treated with potassium supplements or coadministration of potassium-sparing diuretics. Increased calcium ion excretion can be a problem for postmenopausal osteopenic women, and furosemide generally should not be used in these individuals. Hyperuricemia, glucose intolerance, increased serum lipid levels, ototoxicity, and gastrointestinal side effects might be observed as well. Hypersensitivity reactions also are possible with furosemide (a sulfonamide-based drug), and cross-reactivity with other sulfonamide containing drugs is possible.

Safety Profile

Poison by intravenous route. Moderately toxic by ingestion and intraperitoneal routes. Human systemic effects by intravenous route: change in the sensitivity of the ear to sound, tinnitus, unspecified effects on the heart, constriction of the arteries, a decrease in urine volume, interstitial nephritis, metabolic alkalosis, pulse rate decrease, fall in blood pressure. Ingestion can damage the liver. Experimental teratogenic and reproductive effects. Questionable carcinogen with experimental carcinogenic effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of Cl-, NOx, and SOx.

Synthesis

Furosemide, 4-chloro-N-furfuryl-5-sulfamoylanthranylic acid (21.4.11), is synthesized in a relatively simple manner from 2,4-dichlorobenzoic acid, which is converted into 5-aminosulfonyl-4,6-dichlorobenzoic acid (21.4.10) during subsequent reaction with chlorosulfonic acid and ammonia. Reacting this with furfurylamine gives furosemide (21.4.11) .

Veterinary Drugs and Treatments

Furosemide is used for its diuretic activity in all species. It is used in small animals for the treatment of congestive cardiomyopathy, pulmonary edema, hypercalcuric nephropathy, uremia, as adjunctive therapy in hyperkalemia and, occasionally, as an antihypertensive agent. In cattle, it is approved for use for the treatment of post-parturient udder edema. It has been used to help prevent or reduce epistaxis (exercise-induced pulmonary hemorrhage; EIPH) in racehorses.

Drug interactions

Potentially hazardous interactions with other drugs Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect with NSAIDs. Anti-arrhythmics: risk of cardiac toxicity with anti-arrhythmics if hypokalaemia occurs; effects of lidocaine and mexiletine antagonised. Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid with lymecycline. Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics. Antiepileptics: increased risk of hyponatraemia with carbamazepine; effects antagonised by phenytoin. Antifungals: increased risk of hypokalaemia with amphotericin. Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs. Antipsychotics: increased risk of ventricular arrhythmias with amisulpride or pimozide (avoid with pimozide) if hypokalaemia occurs; enhanced hypotensive effect with phenothiazines. Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias. Cardiac glycosides: increased toxicity if hypokalaemia occurs. Ciclosporin: variable reports of increased nephrotoxicity, ototoxicity and hepatotoxicity. Cytotoxics: concentration of furosemide increased by dasabuvir, ombitasvir and paritaprevir - reduce furosemide dose; increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds. Lithium: risk of toxicity.

Metabolism

Little biotransformation of furosemide takes place. It is mainly eliminated via the kidneys (80-90%); a small fraction of the dose undergoes biliary elimination and 10-15% of the activity can be recovered from the faeces.

references

[1]. hochman dw. the extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide. epilepsia, 2012, 53 suppl 1: 18-25. [2]. chen h, sun d. the role of na-k-cl co-transporter in cerebral ischemia. neurol res, 2005, 27(3): 280-286.[3]. prandota j. furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. am j ther, 2002, 9(4): 317-328.

Chemical properties

white or white alike crystalline powder. 206 ℃ melting point. Dissolved in acetone, methanol, dimethyl formamide, slightly soluble in ethanol, insoluble in water. Odorless, almost tasteless.

Category

Toxic substances

Definition

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration and anti-hypertensive agent.

Brand name

Lasix (Sanofi Aventis).

General Description

Odorless white to slightly yellow crystalline powder. A diuretic drug. Almost tasteless.

InChI:InChI=1/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

54-31-9 Relevant articles

Biliary excretion of furosemide glucoronide in rabbits

Sekikawa,Yagi,Oda,Kenmotsu,Takada,Chen,Lin,Benet

, p. 447 - 453 (1995)

Furosemide (F) was administered to rabbi...

Toward Drug Release Using Polymer Mechanochemical Disulfide Scission

Shi, Zhiyuan,Wu, Jingnan,Song, Qingchuan,G?stl, Robert,Herrmann, Andreas

, p. 14725 - 14732 (2020)

Traditional pharmacotherapy suffers from...

Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease

Liu, Xiaojing,Pasangulapati, Jagadeesh Prasad,Schier, Stephanie (Wohnig),Stover, Kurt R.,Wang, Yanfei,Wang, Zhiyu,Weaver, Donald F.

supporting information, (2021/07/28)

β-Amyloid (Aβ) triggered proteopathic an...

Furosemide and purification method thereof

-

Page/Page column 0035-0036; 0038, (2021/06/23)

The invention discloses furosemide and a...

1/20 water-containing furosemide compound and preparation method thereof

-

Paragraph 0038-0052, (2020/01/12)

The invention discloses a 1/20 water-con...

FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE

-

Paragraph 0056; 0059; 0062-0063; 0066-0068, (2021/01/23)

The present application provides furosem...

54-31-9 Process route

furan-2-ylmethanamine
617-89-0

furan-2-ylmethanamine

4-chloro-2-fluoro-5-sulfamoylbenzoic acid
4793-22-0

4-chloro-2-fluoro-5-sulfamoylbenzoic acid

4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
54-31-9

4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid

Conditions
Conditions Yield
With triethylamine; In ethylene glycol; at 130 ℃; for 16h;
76%
With N-ethyl-N,N-diisopropylamine; In 1,2-dimethoxyethane; at 130 ℃; for 16h;
126 mg
methyl 4-chloro-2-[((furan-2-yl)methyl)amino]-5-sulfamoylbenzoate
4793-48-0

methyl 4-chloro-2-[((furan-2-yl)methyl)amino]-5-sulfamoylbenzoate

4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid
54-31-9

4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid

Conditions
Conditions Yield
With water; sodium hydroxide; In ethanol; at 20 ℃;
88.5%

54-31-9 Upstream products

  • 72967-59-0
    72967-59-0

    Furosemide glucuronide

  • 2736-23-4
    2736-23-4

    2,4-dichloro-5-sulfamoylbenzoic acid

  • 41733-55-5
    41733-55-5

    4-chloro-N-(2-furfuryl)-5-sulfamoylanthranilic acid sodium salt

  • 617-88-9
    617-88-9

    2-Chloromethylfuran

54-31-9 Downstream products

  • 4818-85-3
    4818-85-3

    2-furfurylamino-5-sulfamoyl-benzoic acid

  • 137-65-5
    137-65-5

    2-amino-5-sulfamoylbenzoic acid

  • 3086-91-7
    3086-91-7

    4-chloro-5-sulfamoylanthranilic acid

  • 14032-66-7
    14032-66-7

    5-hydroxy-2-(5H)-furanone

Relevant Products